Beta
Back to RXRX.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
cash-flow-chart

RXRX Cash Flow

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

In Q4'25, RXRX's Operating Cash Flow stood at -$46.1M USD, marking a notable improvement from the more negative figures in prior quarters, while Free Cash Flow was -$47.3M USD, reflecting similar positive momentum amid ongoing operational investments. Over the period from Q1'23 to Q4'25, both Operating and Free Cash Flow have remained consistently negative, indicating sustained cash burn typical of a growth-stage biotech firm, with values fluctuating between -$59.2M and -$131.96M for Operating Cash Flow and -$63.8M to -$133.79M for Free Cash Flow. The trend shows volatility, with a deepening deficit in Q1'25 (-$132M for Operating) followed by a gradual recovery in Q4'25, suggesting potential stabilization in cash management despite no positive flows achieved.